Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications

International Journal of Risk and Safety in Medicine

Volumn 24, Issue 3, 2012, Pages 137-146

  Paczynski, Richard P ^a,b   Alexander, G Caleb ^c   Chinchilli, Vernon M ^d   Kruszewski, Stefan P ^a  

^a SPKMD and Associates   (United States)

^b Central Neurological Services   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

antipsychotics; conflict of interest; Drug compendia; recommendations for use; resource utilization

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SYNTHESIS; EVIDENCE BASED MEDICINE; HEALTH CARE UTILIZATION; HUMAN; OFF LABEL DRUG USE; PRESCRIPTION;

ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; DRUG LABELING; EVIDENCE-BASED MEDICINE; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; OFF-LABEL USE; PHARMACOPOEIAS AS TOPIC; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866642808     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2012-0567     Document Type: Article

References (25)

1. Tillman K, Burton B, Jacques LB, Phurrough SE. Compendia and anticancer therapy under medicare. Ann Intern Med. 2009;150:348-50.
2. American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J Clin Oncol. 2006;24:3206-8.
3. Centers for Medicare and Medicaid Services Medicare Coverage Database. Available at: http://www.cms.gov/mcd/ncpc view document.asp?id=16 (Accessed January 27, 2011).
4. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44:136-41.
5. Fulda TR, Valuck RJ, Zander JV, Parker S, Byrns PJ, for the US Pharmacopeia Drug Utilization Review Advisory Panel. Disagreementamongdrugcompendiaoninclusionratingsofdrug-druginteractions.Curr Ther ResClincExp.2000;61:540-8.
6. Abernethy AP, Gowri R, Balk EM, et al. Reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150:336-43.
7. Agency for Healthcare Research and Quality. Technology Assessment. White Paper: Potential Conflict of Interest in the Production of Drug Compendia. Project ID: CMPE 1207. Final Report, April 27, 2009.
8. Federal Register, Rule and Regulations. Vol. 72, No. 227 (November 27, 2007). Available at: http://www.cms.gov/ CoverageGenInfo/02 compendia.asp (Accessed January 31, 2011).
9. LeMasurier JD, Edgar B. MIPPA: First broad changes to Medicare D plan operations. American Health & Drug Benefits. 2009;2:111-8.
10. Brown L. The new compendia landscape: Reimbursement changes to expect and anticipated impact on manufacturers. AmeriSourceBergen Specialty Group, December 10, 2008. Available at: www.absgwebcasts.com/archives.cfm (Accessed January 27, 2011).
11. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medicines, 1995-2008. Pharmacoepidemiology and Drug Safety. 2011;20:177-84.
12. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of veterans affairs health care system. Psychiatr Serices. 2009;60:1175-81
13. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK, for the CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-10.
14. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the Treatment of Early-onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry. 2008;165:1420-31.
15. Rosenheck RA, Leslie DL, Busch S, et al. Rethinking antipsychotic formulary policy. Schizophrenia Bulletin. 2008;34:375-80.
16. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006; Issue 1. Art. No.CD003476.
17. Fedorowicz VJ, Eric Fombonne E. Metabolic side effects of atypical antipsychotics in children: A literature review. J Psychopharmacol. 2005;19:533-50.
18. Alexander GC. Clinical prescribing (and off-label use) in a second-best world. Medical care. 2010;48:285-7.
19. Chen DT, Wynia MK, Moloney RM, Alexander GC. Physician knowledge of the FDA-approved indications of commonly prescribed drugs: results of a national survey. Pharmacoepidemiology and Drug Safety. 2009;18:1094-100.
20. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Medical Care. 2008;46:394-402.
21. Medicare Advantage and prescription drug programs: MIPPA drug formulary & protected classes policies. Federal Register. 2009;74:2881-2888. Available at: http://edocket.access.gpo.gov/2009/pdf/E9-783.pdf (Accessed January 30, 2009).
22. Meron D. How important is an indication? Off-label promotion and compendia. FDLI Conference on Better Understanding CMS and its Relationship to FDA, November 19, 2008. Available at: www.fdli.org/conf/handouts/Meron.pdf (Accessed February 12, 2010).
23. Trailblazers Health Enterprises. Requesting Coverage for Drugs and Biologicals. Available at: http://www. trailblazerhealth.com/Publications/ Job%20Aid/RequestingCoverageforDrugsandBiologicals.pdf (Accessed January 20, 2010).
24. Sidley Austin LLP. Florida drops appeal for Edmonds v. Levine; forces state to pay for recognized off-label uses of Neurontin. Health Care Industry Update, March 7, 2007. http://www.sidley.com/sidleyupdates/Detail.aspx?news=3109 (Accessed February 1, 2011).
25. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-6.